Tarcocimab Tedromer (KSI-301)
Diabetic Retinopathy / Non-Proliferative Diabetic Retinopathy (without DME)
Key Facts
About Kodiak Sciences
Kodiak Sciences is a public biopharma company singularly focused on developing and commercializing novel, durable treatments for the leading causes of blindness. Its core innovation is the ABCD platform, which conjugates antibodies to a proprietary phosphorylcholine-based biopolymer to extend ocular half-life and enable high drug-antibody ratios for multi-mechanistic therapies. The company has advanced its lead asset, tarcocimab, through multiple Phase 3 trials, built a commercial-scale manufacturing facility, and is expanding its pipeline with bispecific candidates like KSI-501 and KSI-101.
View full company profileAbout Kodiak Sciences
Kodiak Sciences is a public biopharma company singularly focused on developing and commercializing novel, durable treatments for the leading causes of blindness. Its core innovation is the ABCD platform, which conjugates antibodies to a proprietary phosphorylcholine-based biopolymer to extend ocular half-life and enable high drug-antibody ratios for multi-mechanistic therapies. The company has advanced its lead asset, tarcocimab, through multiple Phase 3 trials, built a commercial-scale manufacturing facility, and is expanding its pipeline with bispecific candidates like KSI-501 and KSI-101.
View full company profileAbout Kodiak Sciences
Kodiak Sciences is a public biopharma company singularly focused on developing and commercializing novel, durable treatments for the leading causes of blindness. Its core innovation is the ABCD platform, which conjugates antibodies to a proprietary phosphorylcholine-based biopolymer to extend ocular half-life and enable high drug-antibody ratios for multi-mechanistic therapies. The company has advanced its lead asset, tarcocimab, through multiple Phase 3 trials, built a commercial-scale manufacturing facility, and is expanding its pipeline with bispecific candidates like KSI-501 and KSI-101.
View full company profileAbout Kodiak Sciences
Kodiak Sciences is a public biopharma company singularly focused on developing and commercializing novel, durable treatments for the leading causes of blindness. Its core innovation is the ABCD platform, which conjugates antibodies to a proprietary phosphorylcholine-based biopolymer to extend ocular half-life and enable high drug-antibody ratios for multi-mechanistic therapies. The company has advanced its lead asset, tarcocimab, through multiple Phase 3 trials, built a commercial-scale manufacturing facility, and is expanding its pipeline with bispecific candidates like KSI-501 and KSI-101.
View full company profile